• 1
    Mangelsdorf DJ, Thummel C, Beato M et al. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 8359.
  • 2
    Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 1999; 20: 64988.
  • 3
    Jiang C, Ting AT, Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 826.
  • 4
    Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93: 24152.
  • 5
    Spiegelman BM. PPARγ in monocytes: less pain, any gain? Cell 1998; 93: 1535.
  • 6
    Koeffler HP. Peroxisome proliferator-activated receptor γ and cancers. Clin. Cancer Res. 2003; 9: 19.
  • 7
    Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 2004; 5: 41929.
  • 8
    Yuan J, Takahashi A, Masumori N et al. Ligands for peroxisome proliferator-Activated receptor gamma have a potent antitumor effect against human renal cell carcinoma. Urology 2005; 65: 5949.
  • 9
    Terashita Y, Sasaki H, Haruki N et al. Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer. Jpn. J. Clin. Oncol. 2002; 32: 23843.
  • 10
    Sasaki H, Tanahashi M, Yukiue H et al. Decreased perioxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer. Lung Cancer 2002; 36: 716.
  • 11
    Aldred MA, Morrison C, Gimm O et al. Peroxisome proliferator-activated receptor γ is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas. Oncogene 2003; 22: 341216.
  • 12
    Sarraf P, Mueller E, Smith WM et al. Loss-of-function mutations in PPARγ associated with human colon cancer. Mol. Cell 1999; 3: 799804.
  • 13
    Miyao N, Tsukamoto T, Kumamoto Y. Establishment of three human renal cell carcinoma cell lines (SMKT-R-1, SMKT-R-2, and SMKT-R-3) and their characters. Urol. Res. 1989; 17: 31724.
  • 14
    Otani N, Tsukamoto T, Kumamoto Y, Miyao N. Study on in vivo invasive potential of renal cell carcinoma cell lines and effect of growth factors (EGF and TGF-β1) on their in vivo invasions. Jpn. J. Urol. 1991; 82: 61319.
  • 15
    Sobin LH, Wittekind C. TNM Classification of Malignant Tumours, 6th edn. Wiley-Liss, New York, 2002; 1935.
  • 16
    Pavan L, Tarrade A, Hermouet A et al. Human invasive trophoblasts transformed with simian virus 40 provide a new tool to study the role of PPARγ in cell invasion process. Carcinogenesis 2003; 24: 132536.
  • 17
    Haslmayer P, Thalhammer T, Jager W et al. The peroxisome proliferator-activated receptor γ ligand 15-deoxy-Δ12,14-prostaglandin J2 induces vascular endothelial growth factor in the hormone-independent prostate cancer cell line PC 3 and the urinary bladder carcinoma cell line 5637. Int. J. Oncol. 2002; 21: 91520.
  • 18
    DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA. The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers. Carcinogenesis 1998; 19: 4953.
  • 19
    Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y. Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p27KiP1 in human pancreatic carcinoma cells. Cancer Res. 2000; 60: 555864.
  • 20
    Inoue K, Kawahito Y, Tsubouchi Y et al. Expression of peroxisome proliferator-activated receptor γ in renal cell carcinoma and growth inhibition by its agonists. Biochem. Biophys. Res. Commun. 2001; 287: 72732.
  • 21
    Ikezoe T, Miller CW, Kawano S et al. Mutational analysis of the peroxisome proliferator-activated receptor γ gene in human malignancies. Cancer Res. 2001; 61: 530710.
  • 22
    Shuin T, Kondo K, Torigoe S et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 1994; 54: 28525.
  • 23
    Jiang WG, Douglas-Jones A, Mansel RE. Expression of peroxisome-proliferator activated receptor-gamma (PPARγ) and the PPARγ co-activator, PGC-1, in human breast cancer correlates with clinical outcomes. Int. J. Cancer 2003; 106: 7527.
  • 24
    Marques AR, Espadinha C, Frias MJ et al. Underexpression of peroxisome proliferator-activated receptor (PPAR) γ in PAX8/PPARγ-negative thyroid tumours. Br. J. Cancer 2004; 91: 7328.
  • 25
    Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol. 1993; 9: 54173.
  • 26
    Ohta T, Elnemr A, Yamamoto M et al. Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, modulates the E-cadherin/beta-catenin system in a human pancreatic cancer cell line, BxPC-3. Int. J. Oncol. 2002; 21: 3742.